Poor sleep quality is common in patients with heart failure. The limited available evidence
intimates that improving sleep quality in patients with heart failure may improve morbidity
and quality of life in this patient population. However, there is a paucity of evidence
assessing the use of effective pharmacologic therapies in heart failure. The
nonbenzodiazepine, GABA receptor agonist, zolpidem, has been found to have considerable
benefits over traditional benzodiazepines as a soporific medication. The investigators
hypothesize that zolpidem will safely improve sleep quality in patients with heart failure.